Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

Catégorie d'article: research article

Publié en ligne: 14 août 2022

Pages: 371 - 379

Reçu: 31 janv. 2022

Accepté: 07 avr. 2022

DOI: https://doi.org/10.2478/raon-2022-0025

Mots clés

real-world study, non-small cell lung cancer, epidermal growth factor receptor, T790M testing, attrition

© 2022 Nina Turnsek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.